Experimental studies of immune mechanisms in glomerulonephritis date from the beginning of this century', Lindemann produced a model for nephrotoxic glomerulonephritis in 1900 by injecting rabbits with heterologous antiserum to rabbit kidney raised in guinea pigs. In 1907, Von Pirquetf suggested that circulating immune complexes in experimental serum sickness could form a 'toxic compound' and cause nephritis. The first speaker Dr Ph J Hoedemaeker (State University, Leiden, The Netherlands) described how the current models of experimental glomerulonephritis have developed from these early studies. Modern experimental models are either kidney restricted or systemic. Alternatively, glomerulonephritis may be mediated by toxin, cell or antibody. Antibody-mediated glomerulonephritis involves interaction of antibody with an intrinsic renal antigen, as in Heymann nephritis, or with a sequestered exogenous antigen, as in serum sickness nephritis. Heymann nephritis, a model for membranous glomerulonephritis, can be induced by immunizing rats with proximal brush border antigen FxIA. Electron microscopy reveals characteristic electron-dense deposits on the epithelial side of the glomerular basement membrane. These deposits consist of immune complexes and contain brush border antigen:'. Studies to define the nature of the antigen are in progress: a glycoprotein of 330kD, known as Gp330, is present on epithelial cells and has been found in the immune deposits, but FxIA contains at least one other nephritogenic antigen. The glycoprotein Gp90 is also antigenic and may participate in the pathogenesis of Heymann's nephritis.
A new model of antibody-mediated glomerulonephritis has recently been developed. Nephritis is produced by using a monoclonal antibody to mouse Tcell Thy-I antigen. Experimental mercuric chlorideinduced nephritis represents the toxin-induced glomerulonephritis. In the Brown-Norway rat, but not in some other strains, mercuric chloride induces a self-limiting autoimmune disease characterized by the appearance of antiglomerular basement membrane antibodies followed by immune complex disease". Antiglomerular basement membrane antibodies and proteinuria can be suppressed by cyclosporin A. However, some strains of rat show antibodies to glomerular basement membrane without proteinuria. This model illustrates how toxic agents could induce an autoimmune glomerulonephritis in genetically predisposed subjects.
An experimental model of focal segmental glomerulosclerosis has been produced by unilateral nephrectomy in Wistar rats. This results in glomerular hyperfiltration and focal sclerosis in the remnant kidney which can be prevented by captopril', Captopril may prevent renal damage in other clinical situations associated with hyperfiltration-induced glomerular injury.
Dr C M Lockwood (Royal Postgraduate Medical School, London) reviewed rapidly progressive glomerulonephritis in Goodpasture's syndrome and Wegener's granulomatosis. Goodpasture's syndrome is characterized by glomerulonephritis and lung haemorrhage caused by glomerular basement membrane antibodies. Diagnosis is suggested by linear fluorescence on renal biopsy and confirmed by radioimmunoassay of circulating antiglomerular basement membrane antibodies. There is an increased incidence of HLA DR2 in patients with Goodpasture's syndrome. If combined treatment with steroids, cyclophosphamide or azathioprine, and plasmapheresis is initiated early, before the serum creatinine rises above 600 Jlmol/l, then the prognosis for recovery of renal function is good, unless dialysis is required". With combined therapy, there is a fall in glomerular basement membrane antibody . levels and they usually become undetectable by eight weeks. Without treatment antiglomerular basement membrane antibodies may persist for 15 months, but eventually disappear.
Goodpasture's syndrome appears to be a 'one-shot' disease and recurrence is extremely rare. Subclass analysis of glomerular basement membrane antibodies shows a preponderance ofIgG I and IgG 4 • Both subclasses bind to kidney, but whereas IgG J antibodies are complement-fixing and engage macrophage Fc receptors, IgG 4 antibodies may cause little injury since they do not bind these amplifiers oftissue .damage. It is suggested that preferential encouragement of the production of IgG 4 antibodies might influence the course of the disease.
In contrast to rapidly progressive glomerulonephritis caused by glomerular basement membrane antibodies, less is known about the pathogenesis and progress of glomerulonephritis caused by systemic vasculitis. Recently, autoantibodies to neutrophils and monocytes have been demonstrated in patients with Wegener's granulomatosis7. These IgG antibodies recognize cytoplasmic antigens in neutrophils from patients with Wegener's granulomatosis and from normal subjects. The anti-neutrophil antibody titre is highest when the disease is active and falls with remission. The pattern of anti-neutrophil antibody activity is specific for Wegener's granulomatosis, and differs from that seen in both microscopic polyarteritis and hydrallazine-induced rapidly progressive glomerulonephritis. It may therefore be possible to identify serological markers for this group of vasculitides. Cell receptors to ligands of the complement system are found on many cell surfaces. Follicular dendritic cells possess CRI, CR2, CR3, B lymphocytes CR1, CR2, neutrophils, eosinophils, monocytes CR1, CR3 and erythrocytes CRl. CR1 binds C3b, CR2 binds C3dg and C3d, CR3 binds C3bi. Erythrocytes are the major source ofCRI in the circulation. CR1 processes C3 bound to immune complexes and converts C3b to C3bi and C3dg and also protects the erythrocytes from complement activation. Immune complexes bound to erythrocytes are cleared by Kuppfer cells in the liver. The number of CRI sites on erythrocytes is genetically determined by two autosomal codominant alleles for high and low numbers of receptors. In systemic lupus erythematosus there is a lack of CRI sites, because of both genetic and acquired factors. This deficiency could explain the defective immune complex handling seen in lupus". Complement activation by immune complexes may lead to hypocomplementaemia and so facilitate immune complex disease".
The role of the 'membrane attack complex' (C5b-9) in causing tissue damage in immune complex nephritis is controversial10. The C5b-9 complex may be involved in the membrane shedding processes of ageing cells and would account for the presence of the C5b-9 complex in normal renal biopsies. The staining for C5b-9 is more extensive in biopsies of membranous nephropathy, mesangioproliferative glomerulonephritis and severe lupus nephritis, perhaps implicating the complex in tissue damage in these diseases. However, the absence of C5b-9 complexes in the early stages of membranous nephropathy when C3 is present, coupled with the poor ability of C5b-9 complex to lyse nucleated cells, argue against a direct role for the membrane attack complex in the immunopathology of renal disease"! .
The role of macrophages in glomerulonephritis was described by Dr V Cattell (St Mary's Hospital, London). The histological changes seen in acute proliferative glomerulonephritis were initially attributed to endocapillary cell proliferation, but in 1953 Jones 12 suggested that the infiltrate was monocytic. Since then a variety of methods, most recently monoclonal antibodies, have identified monocytes and supported a role for monocytes in the pathogenesis of proliferative glomerulonephritis.
Subendothelial interaction of antigen-antibody causes accumulation of blood monocytes in glomerular capillaries, possibly through immune adherence. Cell-mediated immune mechanisms may be involved as macrophage accumulation in experimental glomerulonephritis is preceded by T.lymphocyte accumulation and can be prevented by cyclosporin A 13 • Monocyte secretion causes glomerular damage and proteinura, and may cause glomerular capillary thrombosis; mature monocytes migrate into the mesangium where they may modify mesangial cell function and proliferation and modulate eicosanoid production. Although increased thromboxane B 2 synthesis is the main eicosanoid abnormality in acute experimental glomerulonephritis, recent findings using a thromboxane synthetase inhibitor in passive in situ immune complex glomerulonephritis suggest that thromboxane B 2 does not have an essential role in monocyte chemotaxis, or glomerular injury.
Monocytes may also have a role in glomerular disease separate from the inflammatory reactions described above. Mononuclear phagocytic cells originate from the bone marrow, circulate as monocytes and in tissues behave as inflammatory cells and fixed long-lived macrophages. Resident macrophages with high levels of la antigen expression have been seen in normal glomeruli, and at least some are phagocytic and capable of antigen presentation!". Recent experiments have shown that these are bone marrow-derived cells with a short glomerular life span (3-4 days), and that Ia is induced in situ 48hours after migration into the glomerulus. The presence of these antigen-presenting cells may be important in the induction of glomerulonephritis.
The potential role of platelets in glomerular injury was described by Dr G Neild (Institute of Urology, London). Platelets can be viewed as inflammatory cell fragments derived from the same stem cells as neutrophils and macrophages. It may be difficult to determine if platelets present at a site of injury are there because of primary involvement or as a secondary phenomenon. Platelets may release serotonin, proteases, platelet-derived growth factors and platelet-specific proteins like platelet factor 4 and beta-thromboglobulin, producing increased vascular permeability, cell proliferation and chemotaxis'". Platelets also activate complement. Endothelial damage is followed by platelet activation. In these ways platelets amplify the vascular injury that frequently occurs in patients with glomerulonephritis.
Platelet counts are usually within normal limits in most forms of glomerulonephritis excepting systemic lupus erythematosus. However, in patients with progressive glomerulonephritis, platelet turnover may be increased and platelet survival is shortened. There are reduced intraplatelet and increased plasma levels of serotonin. Intraglomerular platelets can be difficult to identify in renal biopsies, but platelet-related antigens are frequently found in the absence of recognizable platelets!". Irrespective of the primary renal disease, if the glomerular filtration rate is below 20 ml/min there tends to be a progressive deterioration in renal function from hyperfiltration injury. In animal experiments, hyperfiltration is associated with endothelial damage in glomerular capillaries and platelet aggregates. These changes may be prevented by treatment with warfarin or thromboxane synthetase inhibitors!". Therefore antiplatelet agents might slow the decline of renal function caused by hyperfiltration in patients with renal impairment.
In the final presenta tion Dr N Mallick (Manchester Royal Infirmary) discussed the potential role of immunoglobulins in membranous nephropathy. The negative charge on the glomerular basement membrane is now recognized as important in preventing proteinuria 18 • Glomerular protein leak may result from altered glomerular hydraulics, physicochemical changes with disruption of normal glomerular function, or changes in glomerular charge. Glomerular disease is often prolonged and any of these factors may operate in sequence or together. Membranous nephropathy is viewed as an immune complex-induced glomerulopathy, with in situ immune complex formation rather than deposition of circulating complexes 1 9. Secondary membranous nephropathy may be associated with endogenous antigen like carcinoma, exogenous antigen such as hepatitis B or alteration in immunity as found with lymphoma. Membranous nephropathy may also occur in renal transplants as a recurrent or new finding. The 'antigen' in idiopathic membranous nephropathy is likely to be highly cationic and able to bind antibody. Deposition could commence with antibody which would then bind either antigen or an anti-idiotype antibody. Idiopathic membranous nephropathy in Europe is associated with HLA Drw3. Dr Mallick has tried to identify immunoglobulin markers of impaired renal function in patients with idiopathic membranous nephropathy. Serial analysis of the spectrophotometric pattern of immunoglobulins in patients with idiopathic membranous nephropathy, identified an IgG j band which in most patients appeared at the onset of decline in renal function and disappeared when the decline was halted or reversed by steroid therapy. The nature of this marker for 'active' glomerular damage is speculative, but it could represent an idiotypic response to IgG within the glomerulus.
Immunological mechanisms are involved in the pathogenesis of most forms of glomerulonephritis. Since the early immunological studies of experimental nephritis there have been great advances in the knowledge of immune mechanisms in glomerulonephritis, which in turn may lead to improvements in therapy for this often intractable condition.
